Product Pipeline
Find™ TB Test approved in Mexico & Indonesia, EU CE Mark initiated*
Find™ TB+HIV is currently in development
Find™ SARS-CoV-2 approved in Europe CE Marked 2021*
*Resubmission to regulatory bodies for product reassignment (change of ownership) required, scheduled in 2024 (Mexico) and 2025 (Indonesia)
Find™ SARS-CoV-2
Find™ SARS-CoV-2 is an immune agglutination rapid test intended to detect the Spike S1 protein from the SARS-CoV-2 virus that causes COVID-19, in saliva from individuals aged 6 years and older or individuals with clinical symptoms.
Test results are for the detection of SARS-CoV-2 Spike S1 protein antigen. This antigen is generally detectable in saliva specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses.
The test shows an overall Sensitivity of 98.2% and a Specificity of 95.0% in a cohort of samples including the B.1 D614G and the Alpha, Delta and Epsilon variants. For the B.1.529 Omicron variant, the test demonstrated a sensitivity of 97.4% and a specificity of 100%.
The test is analyzed by the Xplora™ Find™ SARS-CoV-2 application.
Find™ TB
Find™ TB is an immune agglutination rapid test detecting antibodies against three independent tuberculosis antigen in blood samples obtained from a finger prick.
The Find™ TB test was developed for near-patient testing based in the Optimal and Minimum required test characteristics for Community-based triage or referral test for identifying people suspected of having TB defined in the document “High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting” published by WHO in 2014.
The test demonstrated a sensitivity of 95.92% and a specificity of 100%.
This test is capable of detecting pulmonary and non-pulmonary cases of tuberculosis.
The test is analyzed by the Xplora™ Find™ TB application.
Find™ TB+HIV (Test in Development)
Find™ TB+HIV is an immune agglutination rapid test detecting antibodies against three independent tuberculosis antigen and two independent HIV antigens in blood samples obtained from a finger prick.
During a validation study, this test demonstrated a sensitivity of 96% for tuberculosis, and 96% for HIV. It also demonstrated a specificity of 93% for tuberculosis and 98% for HIV.
The test is analyzed by the Xplora™ Find™ TB+HIV application.